Of necessity, diagnostic tools are at the heart of the health care system, since they offer means to build a detailed and individualised understanding of patient health and illness. A number of analyst estimates approximate the overall global diagnostics market to be worth US$ 40–45 bn. The bulk of the IVD market is concentrated in developed countries, with the United States (US$ 19 bn), Europe (US$ 14 bn) and Japan (approx. US$ 4 bn) accounting for over 80% of global sales. In recent years, this vital role for diagnostics has been reflected in the performance of this segment. The non-imaging diagnostics segment is booming in 2020, with COVID-19- related diagnostics needed in bulk on the clinical front line. Yet COVID-19 could act as a growth driver for non-imaging diagnostics in the longer term as well.